Multiple antigenic polypeptide composed of heparanase B-cell epitopes shrinks human hepatocellular carcinoma in mice

Abstract

The purpose of this study was to evaluate the anti‑growth effect of the self‑designed multiple antigenic polypeptide (MAP) vaccine comprising B‑cell epitopes of heparanase (HPSE) on HCC97‑H hepatocellular carcinoma (HCC) in mice. The polyclonal antibodies against the B‑cell epitopes of HPSE were prepared by immunizing rabbits with freshly synthesized MAP vaccine. HCC‑bearing models were constructed on BALB/c nude mice. Anti‑MAP antibodies were administrered to the models to assess the effects on HPSE activity, HCC growth, the expression of VEGF/bFGF and the value of micro‑vessel density (MVD). The anti‑MAP antibodies were harvested, purified and identified. These antibodies were able to specifically bind with the dominant epitopes of the precursor protein and large subunit monomer of HPSE, decrease HPSE activity, suppress the expressions of VEGF and bFGF, reduce the MVD, and markedly shrink the HCC volume. Based on these findings, MAP vaccine based on the B‑cell epitopes of HPSE seemed to provide theoretical evidence for further study of the synthesized HPSE MAP vaccine in the treatment of HCC.

Prediction and identification of B-cell epitopes for tumor necrosis factor-α

“…The present study was based on previous investigations of a heparanase MAP vaccination strategy (18)(19)(20)(21)(22), with the establishment of a method to induce a high-titer humoral immune response (23). To achieve the inhibition of TNF-α, internet software was used to predict the TNF-α B-cell epitope and an optimized immunization strategy (MAP + T cell epitope peptide) was used to induce high titers of antibody in vivo.…”

Targeting Angiogenesis With Peptide Vaccines

“…The resulting polyclonal antibodies were then purified from rabbit serum and injected to mice bearing the HCC-97H hepatocarcinoma tumor in different doses. The antibodies reduced the serum levels of VEGF and FGF and decreased MVD, tumor volumes and the number of pulmonary metastasis (56, 57).…”

Complex TNF-α B cell epitope MAP vaccine alleviates murine ulcerative colitis

“…This pattern mimics the natural epitope conformation and can also activate humoral immunity to induce high titer and affinity antibodies without re-coupling the carrier protein (14). Based on previous investigations associated with MAP vaccines, the authors of the current study successfully enhanced heparinase immunogenicity using the MAP design, and obtained high-titer and -affinity anti-heparinase antibodies in vivo (15,16).…”